Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC

Colorectal Cancer Clinical Trial

— PARADIGM  

Official title:

A Phase III, Randomized, Controlled Study of mFOLFOX6 + Bevacizumab Combination Therapy Versus mFOLFOX6 + Panitumumab Combination Therapy in Chemotherapy-naive Patients With KRAS/NRAS Wild-type, Incurable/Unresectable, Advanced/Recurrent Colorectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02394795
• Other study ID #: Panitumumab-3001
• Secondary ID: U1111-1164-9167J
• Status: Completed
• Phase: Phase 3
• Start date: May 29, 2015
• Est. completion date: January 14, 2022

Study information

• Verified date: January 2023
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to verify the efficacy of mFOLFOX6 + panitumumab combination therapy and mFOLFOX6 + bevacizumab combination therapy in first-line treatment of chemotherapy-naive patients with KRAS/NRAS wild-type, incurable/unresectable, advanced/recurrent colorectal cancer.

Description:

The purpose of this study is to verify the efficacy of mFOLFOX6 + panitumumab combination therapy and mFOLFOX6 + bevacizumab combination therapy in first-line treatment of chemotherapy-naive patients with KRAS/NRAS wild-type, incurable/unresectable, advanced/recurrent colorectal cancer.

This study will enroll a total of approximately 800 participants (400 per group).

Participants will be randomized to either the mFOLFOX6 + panitumumab arm (Group P) or mFOLFOX6 + bevacizumab arm (Group B) at 1:1 ratio at the time of registration.

Group P and Group B treatment regimen shown below should be administered once every two weeks, following dose, schedule and route of administration.

Group P; mFOLFOX6 + panitumumab combination therapy, once every two weeks OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg

Group B; mFOLFOX6 + bevacizumab combination therapy, once every two weeks OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg

This trial is conducted by multicenter and is scheduled for 12 months as whole administration period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 823
• Est. completion date: January 14, 2022
• Est. primary completion date: January 14, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 79 Years

Eligibility

Inclusion Criteria:

1. Investigator and subinvestigator judge a candidate is understand clinical trial and comply this protocol.

Investigator is those who participate in conducting a study and oversight the study duties at a site.

2. Patients who have given written consent to take part in the study after detailed explanation of the study prior to enrollment

3. Aged =20 to <80 years at the time of informed consent

4. Patients with unresectable adenocarcinoma originating in the large intestine (excluding carcinoma of the appendix and anal canal cancer)

5. Patients with lesion(s) that can be evaluated. It is not essential to be evaluated the tumor according to the RECIST ver. 1.1.

6. Patients who have not received chemotherapy for colorectal cancer. Patients who experience relapse more than 24 weeks (168 days) after the final dose of perioperative adjuvant chemotherapy with fluoropyrimidine agents may be enrolled. Patients who have received perioperative adjuvant chemotherapy including oxaliplatin are excluded.

7. Patients classified as KRAS/NRAS wild-type by KRAS/NRAS testing. KRAS/NRAS test will be performed using the in vitro diagnostic listed in the National Health Insurance.

Patients with no mutation in any of the codons shown below are considered wild type. It is not considered wild type if either of the codons are not evaluable or not tested.

KRAS: EXON2 (codon 12, 13), EXON3 (codon 59, 61), EXON4 (codon 117, 146) NRAS:EXON2 (codon 12, 13), EXON3 (codon 59, 61), EXON4 (codon 117, 146)

8. Patients who satisfy the following criteria for the major organ function in tests performed within 14 days prior to enrollment

• Neutrophil count = 1.5×10^3/µL

• Platelet count = 1.0×10^4/µL

• Hemoglobin = 9.0 g/dL

• Total bilirubin = 2.0 mg/dL

• AST = 100 IU/L (= 200 IU/L if liver metastases are present)

• ALT = 100 IU/L (= 200 IU/L if liver metastases are present)

• Serum creatinine = 1.5 mg/dL

• PT-INR < 1.5 (< 3.0 for patients treated with oral warfarin)

• Satisfies at least one of these conditions

1. Urine protein (dip stick method) = 1+

2. UPC (urine protein creatinine) ratio = 1.0

3. Urinary protein = 1000 mg/ 24hours

9. ECOG performance status (PS) of 0 or 1

10. Life expectancy of = 3 months (90 days) after enrollment

Exclusion Criteria:

1. Radiotherapy received within 4 weeks (28 days) prior to enrollment. Treatments aimed at relieving pain for bone metastases are excluded.

2. Known brain metastasis or strongly suspected of brain metastasis

3. Synchronous cancers or metachronous cancers with a disease-free period of = 5 years (excluding colorectal cancer) excluding mucosal cancers cured or be possibly cured by regional resection (esophageal, stomach, and cervical cancer, non-melanoma skin cancer, bladder cancer, etc.).

4. Body cavity fluid that requires treatment (pleural effusion, ascites, pericardial effusion, etc.)

5. Patients who do not want to use contraception to prevent pregnancy, and women who are pregnant or breast-feeding, or test positive for pregnancy

6. Nonhealing surgical wound (excluding implanted venous reservoirs)

7. Active hemorrhage requiring blood transfusion

8. Disease requiring systemic steroids for treatment (excluding topical steroids)

9. The patient who has placed colonic stent

10. Intestinal resection within 4 weeks prior to enrollment or colostomy within 2 weeks prior to enrollmentt

11. History or obvious and extensive CT findings of interstitial pulmonary disease (interstitial pneumonia, pulmonary fibrosis, etc.)

12. Patients with unstable angina, myocardial infarction, cerebral hemorrhage, arterial thromboembolism such as cerebral infarction, or have history of these desease less than 24 weeks (168 days) before registration (except for lacunar infarction asymptomatic)

13. Serious drug hypersensitivity

14. Local or systemic active infection requiring treatment, or fever indicating infection

15. NYHA class II or higher heart failure or serious heart disease

16. Intestinal paralysis, gastrointestinal obstruction, or uncontrollable diarrhoea (incapacitating symptoms despite adequate treatment)

17. Poorly controlled hypertension

18. Poorly controlled diabetes mellitus

19. Active hepatitis B

20. Known HIV infection

21. Peripheral neuropathy of = Grade 2 by CTCAE (Japanese edition JCOG version 4.03)

22. Other patients judged by the investigator or subinvestigator to be ineligible for enrollment in the study (e.g. Patients who might agree to participate under compulsion).

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
• oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	OS in Participants With Left-sided Tumors	OS was measured as the time from the date of randomization to the date of death due to any cause. The left-sided tumors were defined as primary tumors occupying a left-sided site include the descending colon, sigmoid colon, and rectum.	Up to approximately 60 months
Primary	Overall Survival (OS) in All Participants	OS was measured as the time from the date of randomization to the date of death due to any cause.	Up to approximately 60 months
Secondary	Progression-Free Survival (PFS) in Participants With Left-sided Tumors	PFS was defined as the time from the date of randomization to the earlier of Progressive Disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or death due to any cause. The left-sided tumors were defined as primary tumors occupying a left-sided site include the descending colon, sigmoid colon, and rectum.	Up to approximately 60 months
Secondary	Progression-Free Survival (PFS) in All Participants	PFS was defined as the time from the date of randomization to the earlier of Progressive Disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or death due to any cause.	Up to approximately 60 months
Secondary	Response Rate (RR) in All Participants	RR was defined as number of participants who achieve Complete Response (CR) and Partial Response (PR) as the best overall response per RECIST version 1.1.The best overall response was CR, followed by PR, stable disease (SD), progressive disease (PD), and not evaluable (NE). CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters as the best overall response after randomization., SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).	Up to approximately 60 months
Secondary	Duration of Response (DOR)	DOR means that the period from the day when either CR or PR is first confirmed until the day of documented PD or the day of death due to all causes, whichever occurs earlier.	Up to approximately 60 months
Secondary	Number of Participants Treated With Curative Surgical Resection After Chemotherapy	Curative surgical resection was defined as complete resection.	Up to approximately 60 months
Secondary	Number of Participants With Treatment-emergent Adverse Events (TEAE)	Adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurred in the treatment period after receiving the protocol treatment.	Up to approximately 60 months

External Links

•   To obtain more information on the study, click here/on this link